Bipolar disorder is what type of disorder?

Serotonin/norepinephrine reuptake inhibitors (SNRIs) are commonly used in the management of major depressive disorder by increasing levels of serotonin and norepinephrine in the brain. When selecting an SNRI, patient-specific factors such as liver function and substance use history must be considered. Certain medications in this class carry a higher risk of hepatotoxicity, which becomes especially concerning in individuals with recent or ongoing alcohol abuse. Careful screening helps prevent drug-induced liver injury.

Rationale:
A. Venlafaxine is an SNRI used to treat depression and anxiety disorders. While it requires monitoring for blood pressure elevation and withdrawal symptoms, it is not specifically contraindicated in patients with a history of alcohol abuse. It does not carry the same degree of hepatotoxic risk as some other SNRIs.

B. Desvenlafaxine is a metabolite of venlafaxine and shares a similar mechanism of action. It is generally well tolerated and does not have a strong association with liver toxicity. Although caution is always advised with substance use history, it is not specifically contraindicated in alcohol abuse.

C. Escitalopram is actually a selective serotonin reuptake inhibitor (SSRI), not an SNRI. While it is commonly used for depression and anxiety, it does not significantly impact norepinephrine levels. It also does not carry a major hepatotoxic risk, but it is not relevant to the SNRI category in this question.

D. Duloxetine is associated with an increased risk of hepatotoxicity, particularly in patients with chronic alcohol use or preexisting liver disease. It is extensively metabolized by the liver, and alcohol-related liver stress can amplify the risk of injury. Because of this, duloxetine is contraindicated in patients with a history of substantial alcohol use.

Opioid tolerance develops with repeated use of medications such as Morphine, leading to a reduced response to the same dose over time. This occurs due to neuroadaptive changes at opioid receptors and downstream signaling pathways. As tolerance increases, higher doses are required to achieve the same therapeutic effect. However, tolerance develops unevenly across different opioid effects.

Rationale:
A. Increased respiratory depression is not expected with tolerance because patients typically develop tolerance to respiratory depressive effects over time. While respiratory depression is a major risk in opioid-naïve individuals, chronic users often require higher doses to produce the same effect. However, this does not eliminate risk, especially with dose escalation.

B. Increased euphoria is not associated with tolerance; instead, tolerance generally reduces the euphoric effects of opioids. Repeated exposure leads to diminished reward response, contributing to dose escalation in some individuals seeking the initial effect. The neurobiological adaptation reduces sensitivity to opioid-induced pleasure.

C. Decreased constipation is incorrect because tolerance develops poorly to gastrointestinal effects of opioids. Constipation persists due to continued reduced gastrointestinal motility from mu-receptor activation in the gut. Patients often require ongoing bowel regimens despite long-term opioid use.

D. Decreased analgesic effect is the hallmark of opioid tolerance. Over time, the same dose produces less pain relief due to receptor desensitization and downregulation. This necessitates higher doses or alternative pain management strategies to maintain adequate analgesia.